About Apricus Biosciences (NASDAQ:APRI)
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:APRI
- CUSIP: N/A
- Web: www.apricusbio.com
- Market Cap: $23.27 million
- Outstanding Shares: 12,783,000
- 50 Day Moving Avg: $1.78
- 200 Day Moving Avg: $1.36
- 52 Week Range: $0.86 - $4.07
Sales & Book Value:
- Trailing P/E Ratio: 2.97
- Foreward P/E Ratio: 1.19
- P/E Growth: 0.00
- Annual Revenue: $5.76 million
- Price / Sales: 3.95
- Book Value: $0.51 per share
- Price / Book: 3.49
- EBITDA: ($10,050,000.00)
- Return on Assets: -91.93%
- Current Ratio: 4.70%
- Quick Ratio: 4.70%
- Average Volume: 379,060 shs.
- Beta: 0.52
- Short Ratio: 3.14
Frequently Asked Questions for Apricus Biosciences (NASDAQ:APRI)
What is Apricus Biosciences' stock symbol?
Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."
How were Apricus Biosciences' earnings last quarter?
Apricus Biosciences, Inc (NASDAQ:APRI) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.01. View Apricus Biosciences' Earnings History.
When will Apricus Biosciences make its next earnings announcement?
Where is Apricus Biosciences' stock going? Where will Apricus Biosciences' stock price be in 2017?
2 brokers have issued twelve-month price objectives for Apricus Biosciences' shares. Their forecasts range from $4.50 to $4.50. On average, they expect Apricus Biosciences' share price to reach $4.50 in the next year. View Analyst Ratings for Apricus Biosciences.
Who are some of Apricus Biosciences' key competitors?
Some companies that are related to Apricus Biosciences include Amryt Pharma PLC (AMYT), Intellipharmaceutics International (IPCI), Pernix Therapeutics Holdings (PTX), Concordia International Corp. (CXRX), Cellectar Biosciences (CLRB), Venture Life Group PLC (VLG), Eyegate Pharmaceuticals (EYEG), Neuralstem (CUR), Galena Biopharma (GALE), Immune Pharmaceuticals (IMNP), Aegerion Pharmaceuticals (AEGR), Amryt Pharma PLC (FAST), Avanir Pharmaceuticals (AVNR), Cadence Pharmaceuticals (CADX), CannTrust Holdings (TRST), CoLucid Pharmaceuticals (CLCD), Forest Laboratories (FRX) and Hi-Tech Pharmacal (HITK).
Who are Apricus Biosciences' key executives?
Apricus Biosciences' management team includes the folowing people:
- Kleanthis G. Xanthopoulos Ph.D., Chairman of the Board
- Richard W. Pascoe, Chief Executive Officer, Principal Accounting Officer, Secretary, Director
- Brian T. Dorsey, Senior Vice President, Chief Development Officer
- Paul V. Maier, Independent Director
- Rusty Ray, Independent Director
- Sandford D. Smith, Independent Director
- Wendell Wierenga Ph.D., Independent Director
How do I buy Apricus Biosciences stock?
Shares of Apricus Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apricus Biosciences' stock price today?
MarketBeat Community Rating for Apricus Biosciences (NASDAQ APRI)MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Apricus Biosciences stock can currently be purchased for approximately $1.78.
Earnings History for Apricus Biosciences (NASDAQ:APRI)Earnings History by Quarter for Apricus Biosciences (NASDAQ APRI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/11/2017||Q1 2017||$1.25||$1.04||$12.00 million||View||N/A|
|3/13/2017||Q4 2016||($0.15)||($0.04)||$3.44 million||$0.40 million||View||N/A|
|11/8/2016||Q316||($0.60)||($0.19)||$1.91 million||$4.30 million||View||Listen|
|8/4/2016||Q216||($0.08)||($0.05)||$1.78 million||$0.46 million||View||Listen|
|5/9/2016||Q116||($0.09)||($0.09)||$0.83 million||$0.63 million||View||N/A|
|3/9/2016||Q415||($0.11)||($0.05)||$1.81 million||$2.60 million||View||Listen|
|11/5/2015||Q315||($0.11)||($0.10)||$1.42 million||$1.30 million||View||Listen|
|8/5/2015||Q2||($0.13)||($0.10)||$0.70 million||$0.46 million||View||Listen|
|5/11/2015||Q1||($0.10)||($0.13)||$0.95 million||$0.48 million||View||Listen|
|3/16/2015||Q4||($0.12)||($0.09)||$0.67 million||$1.91 million||View||Listen|
|11/10/2014||Q314||($0.09)||($0.08)||$1.23 million||$1.90 million||View||N/A|
|3/17/2014||Q212||($0.06)||($0.04)||$2.00 million||$0.36 million||View||N/A|
Earnings Estimates for Apricus Biosciences (NASDAQ:APRI)
2017 EPS Consensus Estimate: ($0.06)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Apricus Biosciences (NASDAQ:APRI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Apricus Biosciences (NASDAQ:APRI)
Insider Ownership Percentage: 3.55%Insider Trades by Quarter for Apricus Biosciences (NASDAQ:APRI)
Institutional Ownership Percentage: 15.27%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/31/2017||Alexander J Denner||Major Shareholder||Buy||6,104||$1.63||$9,949.52|| |
|3/3/2016||Alexander J Denner||Major Shareholder||Buy||6,647,728||$0.88||$5,850,000.64|| |
|1/12/2016||Alexander J Denner||Major Shareholder||Buy||1,306,819||$0.88||$1,150,000.72|| |
|12/29/2014||Brian Dorsey||Insider||Buy||10,000||$1.05||$10,500.00|| |
|12/22/2014||Richard W Pascoe||CEO||Buy||10,000||$1.02||$10,200.00|| |
|10/23/2014||Sandford D Smith||Director||Buy||26,500||$1.57||$41,605.00|| |
|1/3/2014||Leonard A Oppenheim||Director||Sell||15,212||$2.49||$37,877.88|| |
|12/26/2013||Kleanthis G Xanthopoulos||Director||Sell||17,184||$2.55||$43,819.20|| |
|6/21/2013||Kleanthis G Xanthopoulos||Director||Sell||2,864||$2.52||$7,217.28|| |
|5/23/2013||Richard W Pascoe||CEO||Buy||35,000||$2.85||$99,750.00|| |
|5/23/2013||Rusty Ray||Director||Buy||5,000||$2.85||$14,250.00|| |
|5/23/2013||Steven Robert Martin||CFO||Buy||20,000||$2.85||$57,000.00|| |
|5/21/2013||Kleanthis G Xanthopoulos||Director||Sell||2,864||$3.36||$9,623.04|| |
|8/20/2012||Edward M Cox||VP||Buy||1,500||$2.73||$4,095.00|| |
|8/17/2012||Rusty Ray||Director||Buy||4,000||$2.81||$11,240.00|| |
Headline Trends for Apricus Biosciences (NASDAQ:APRI)
Latest Headlines for Apricus Biosciences (NASDAQ:APRI)
Loading headlines, please wait.
Apricus Biosciences (APRI) Chart for Tuesday, October, 24, 2017